TheWell Bioscience is a leader in advanced 3D cell culture, specializing in pioneering xeno-free (animal-free) biofunctional hydrogels that bridge the gap between in vitro and in vivo studies. Their flagship portfolio is centered around VitroGel®, a synthetic polysaccharide hydrogel system that mimics the natural extracellular matrix (ECM) while remaining stable at room temperature.

TheWell Bioscience supports their organoid platform with the VitroPrime™ and RocketCell™ media lines, which are specifically formulated to optimize the growth and maintenance of 3D models. The VitroPrime™ Organoid Base Medium provides a highly stable, defined environment that eliminates the variability often found in standard culture media, ensuring consistent nutrient delivery across various organoid types. To further enhance development, they offer CytoGrow™ supplements, which include precisely calibrated growth factors and cytokines to guide differentiation and long-term expansion.

The Sphericalplate 5D (SP5D), developed by Kugelmeiers, is a specialized 3D cell culture platform designed to generate uniform, size-controlled spheroids with high quality and yield. The portfolio features a patented microwell geometry with a “non-fouling” surface coating that allows for the effortless formation of up to 9,000 standardized cell clusters per plate without the need for centrifugation. The technology is uniquely scalable, allowing researchers to transition seamlessly from small-scale laboratory experiments to large-scale clinical and diagnostic use. Additionally, the plates are made from Cyclic Olefin Copolymer (COC) to ensure high-quality real-time imaging with minimal background noise.

Beonchip offers a specialized portfolio of microfluidic platforms designed to bridge the gap between traditional cell culture and human physiology through Organ-on-Chip (OoC) technology. Their catalog features a range of biomimetic chips, including the Be-Flow for vascular research under shear stress, and the Be-Doubleflow and Be-Transflow, which utilize porous membranes for complex barrier and air-liquid interface (ALI) studies. These devices are manufactured using medical-grade, lipophobic plastics (COP/COC) to prevent non-specific drug adsorption and ensure superior optical clarity for high-resolution imaging. This comprehensive approach enables researchers to create more predictive, animal-free in vitro models across various organ systems.

TissUse GmbH has advanced the organ-on-chip field primarily through its proprietary HUMIMIC platform, which distinguishes itself by integrating multiple miniaturized human organ equivalents—such as liver, skin, and kidney—onto a single microfluidic chip the size of a standard microscope slide. Their core technological leap lies in a self-contained, on-chip micropump that provides pulsatile nutrient flow and vascular perfusion, effectively simulating systemic circulation and homeostatic crosstalk between tissues. This setup allows for long-term co-cultures (up to 28 days or more) and enables complex ADME (Absorption, Distribution, Metabolism, and Excretion) and toxicity profiling. By replicating physiological shear stress and near-natural tissue-to-fluid ratios, TissUse’s technology provides a predictive “human-on-a-chip” model that significantly reduces the reliance on animal testing for drug development and safety assessment.

REPROCELL has moved beyond simple research kits to establish a comprehensive clinical iPSC ecosystem, headlined by their StemRNA™ Clinical platform. This technology utilizes a footprint-free, mRNA-based reprogramming method that is up to 50 times more efficient than traditional episomal techniques, ensuring high genetic stability without the risk of viral integration. As of 2026, they have bridged the gap to clinical application with FDA-compliant GMP Master Cell Banks (MCB) and the StemEdit™ service, which leverages AI-designed nucleases for high-precision gene editing in iPSCs